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The possible association of infant vaccinations with risk of child-
hood leukaemia has been of interest for more than 30 years. In a
small hospital-based case-control study of childhood leukaemia in
Australia, an excess of diphtheria, tetanus and pertussis (DTP)
vaccinations was observed among the cases (Innis, 1965).
Subsequent studies, however, did not confirm this finding. The
large, population-based Oxford Survey of Childhood Cancer
reported protective effects from smallpox, diphtheria, tetanus,
pertussis, measles, rubella, poliomyelitis and bacille Calmette-
Gu￿rin (BCG) vaccines among 5636 children with all forms of
leukaemia (Kneale et al, 1986). Similarly, a case-control study of
British children with all leukaemias reported a significantly
reduced risk of leukaemia among children who received tetanus,
diphtheria, pertussis, smallpox, polio and/or measles vaccines
(McKinney et al, 1987). Also, a small case-control study of non-
T-cell acute lymphoblastic leukaemia (ALL) in Japan reported
protective effects for both BCG and measles vaccination (Nishi
and Miyake, 1989), whereas a study of children with all leukaemia
types in Germany reported a protective effect of unspecified vacci-
nations (Kaatsch et al, 1996).
We carried out a large case-control investigation of potential
risk factors for childhood ALL conducted collaboratively by the
National Cancer Institute (NCI) and the Children￿s Cancer Group
(CCG) among children diagnosed prior to age 15. To investigate
the influence of vaccination on ALL risk, we evaluated recorded
information for all vaccines recommended for routine use in
infancy among 439 ALL cases and an equal number of matched
controls in nine Midwestern and Mid-Atlantic states in the USA.
METHODS
Patients with ALL aged 0—14, diagnosed between 1989 and 1993,
were enrolled in the study (Kleinerman et al, 1997). Subjects who
resided in Illinois, Indiana, Iowa, Michigan, Minnesota, New
Jersey, Ohio, Pennsylvania, or Wisconsin at the time of diagnosis
were eligible for the vaccination component of the study. Controls
selected through random-digit dialing (Robison and Daigle, 1984)
were individually matched to the cases by age (within 25% of the
corresponding case￿s age at diagnosis), the first eight digits of the
telephone number, and race (African-American/white/other).
There were three separate components of this study, as described
earlier (Kleinerman et al, 1997). Mothers of 96% of eligible cases
and 75% of eligible controls from the nine states completed an
initial telephone interview, and mothers of 788 (98%) and 699
(97%) eligible cases and controls, respectively, participated in a
subsequent in-person interview. In the third component, vaccina-
tion data were provided by mothers (based on vaccination records
from physicians) or obtained directly from the physicians of 630
(79.9%) cases and 550 (78.7%) controls, representing overall
participation rates of 70.1% for cases and 50.4% for controls.
There were 439 matched pairs for whom vaccination data were
collected.
Data collection forms, completed by the mothers using vaccina-
tion records from physicians or by the physicians themselves,
inquired whether and when the child had received oral or injected
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20892-7244, USApoliovirus vaccine, trivalent diphtheria—tetanus—pertussis vaccine,
bivalent diphtheria—tetanus vaccine, bivalent tetanus—diphtheria
vaccine, monovalent tetanus vaccine, trivalent measles—
mumps—rubella vaccine, Haemophilus influenzae group b (Hib)
vaccines, hepatitis B virus vaccine and other vaccines. For 329
(75%) of the cases and 334 (76%) of the controls among the 439
matched pairs, the mother provided vaccination records, and the
physician was not contacted. With the mother￿s permission, a
medical-record request was filed with the subject￿s primary physi-
cian, requesting details and dates of vaccination for the remaining
subjects.
Vaccination data were sought but not obtained from 158 of the
788 cases whose mothers were interviewed in-person, of whom 63
were due to maternal refusal, and 94 were due to physician refusal
or non-response. Likewise, 84 maternal refusals and 63 physician
refusals or non-responses were the main reasons for the 149
controls without vaccination data among the 699 controls whose
mothers were interviewed in-person. Vaccination data were coded
up to the date of diagnosis for cases, and up to the date of inter-
view for controls.
To ensure that the case and control within each pair were
observed for the same length of time, we censored the vaccination
data by adopting a common ￿cut-off-age￿ (the lesser of the age at
diagnosis for the case or the age at interview for the control) for
both members of each matched pair, excluding from analysis any
vaccine doses received after the cut-off age. We calculated relative
risks and 95% confidence intervals for ALL following exposure to
each vaccine (ever vs never vaccinated). We also evaluated
number of doses of vaccine received, age at first dose, age at last
dose, time between first dose of each vaccine and diagnosis, and
time between last dose of each vaccine and diagnosis. Since none
of these analyses contributed additional useful information, only
the ever- versus never-vaccinated results are presented here.
Relative risks (RR) and 95% confidence intervals (CI) were
calculated by conditional logistic regression (Breslow and Day,
1980) using a matched-pairs design and adjusting for age (in
years) at censoring, year of birth, sex, race, family income and
parental education, as shown in Table 1. For nine subjects (seven
cases and two controls) with unknown family income, the median
family income among controls was imputed as the subject￿s family
income. For the fathers of 31 subjects (12 cases and 19 controls)
whose level of education was unknown, the median education
level from the controls was imputed. Since early day-care or
preschool attendance has been linked with decreased risk of ALL
in prior studies (Petridou et al, 1993), we adjusted for these
variables as well.
Monovalent injected vaccines to protect against hepatitis B
virus, tetanus and poliovirus were received by fewer than 1% of
subjects, and monovalent vaccines to protect subjects from
Neisseria meningitidis, Mycobacterium tuberculosis, varicella, or
mumps, were received by very few subjects. Therefore, none of
these vaccines were separately analysed. Although few subjects
received monovalent or bivalent vaccines against tetanus and/or
diphtheria, summary variables were created to integrate all
possible vaccine doses containing tetanus or diphtheria toxoids.
The first Hib vaccine approved by the US Food and Drug
Administration was a polysaccharide vaccine licensed in April
1985. A single dose was to be administered at the age of 24
months (Advisory Committee on Immunization Practices, 1985),
or at 18 months for those in day-care, since early day-care atten-
dance was linked with increased risk of invasive Hib infection in
several US studies (Redmond and Pichichero, 1984; Istre et al,
1985; Cochi et al, 1986). The first conjugate vaccine was licensed
in December 1987; a single dose was to be administered at the age
of 18 months (Advisory Committee on Immunization Practices,
1988). The first doses of conjugate vaccine were shipped in
1988 (Adams et al, 1993). In 1990, two conjugate Hib vaccines,
developed subsequent to the first formulation, were recommended
for use in four doses at the ages of 2, 4, 6 and 15 months (Advisory
Committee on Immunization Practices, 1991).
Since the vaccine records provided by mothers or physicians did
not specify the type of Hib vaccine, any dose administered before
1 January 1988 was assumed to be polysaccharide Hib vaccine for
purposes of this study; doses administered on or after that date
were assumed to be the conjugate Hib vaccine. Only 29 subjects
(14 cases and 15 controls) received more than one dose of Hib
vaccine; 28 of these were born after 1988 and presumably received
only conjugate vaccine. Due to small numbers, it was deemed
impossible to assess the effect of multiple doses of Hib vaccine.
No subject received Hib vaccine doses both before and after
1 January 1988. For the analysis of Hib vaccine effects, the
polysaccharide and conjugate vaccine types were modelled simul-
taneously, and the reference group included only those subjects
who received neither type.
RESULTS
Demographic data on cases and controls (Table 1) show that cases
came from families with lower income and parental education than
controls, but there were few differences in year of birth, age at
censoring, or attendance at day-care or preschool. Results for
individual vaccines, as well as for the two summary variables
reflecting all exposures to tetanus or diphtheria toxoids, are
shown in Table 2. The vast majority of subjects received at least
one dose of three major vaccines: oral poliovirus (98%), diph-
theria—tetanus—pertussis (97%), and measles—mumps—rubella
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Table 1 Characteristics of cases and controls (439 pairs)
Cases Controls
Male 234 (53%) 248 (56%)
Born
1974–1984 142 (32%) 139 (32%)
1985–1987 175 (40%) 174 (40%)
1988–1992 122 (28%) 126 (29%)
Age at censoring
< 6 months 119 (27%) 119 (27%)
36–60 months 144 (33%) 144 (33%)
> 60 months 176 (40%) 176 (40%)
Day-care (ever) 137 (31%) 135 (31%)
Preschool (ever) 162 (37%) 177 (40%)
Family income
< $20 000 91 (23%) 66 (17%)
$20 000–$29 999 118 (30%) 101 (25%)
$30 000–$39 999 84 (21%) 91 (23%)
$40 000+ 105 (26%) 140 (35%)
Mother’s education
High School graduate or less 184 (42%) 168 (38%)
Some post-High-School education 145 (33%) 139 (32%)
College graduate 110 (25%) 132 (30%)
Father’s education
High School graduate or less 187 (43%) 148 (34%)
Some post-High-School education 126 (29%) 137 (31%)
College graduate 126 (29%) 154 (35%)(90%). None of these vaccines significantly altered the risk of
subsequent ALL.
Hib vaccine in some form was received by 53% of controls
versus 47% of cases (RR = 0.73; 95% CI 0.50—1.06). Similar
proportions of cases (12%) and controls (11%) received the
polysaccharide Hib vaccine (RR = 1.13; 95% CI 0.64—1.98). A
higher proportion of controls (41%) than cases (35%) received
the conjugate Hib vaccine; thus, the conjugate Hib vaccine was
associated with a significantly reduced risk of subsequent ALL
(RR = 0.57; 95% CI 0.36—0.89). When the effect of Hib vaccina-
tion was analysed for three different birth cohorts (pre-1984,
1984—1986, and post-1986), the reduced risk was seen only among
children born after 1986, who presumably received only the conju-
gate Hib vaccine (data not shown). Neither age at vaccination nor
interval between vaccination and diagnosis affected the risk of
ALL following any of the vaccines; nor did number of doses of
OPV or DTP (data not shown).
DISCUSSION
Several vaccines commonly administered to US infants have been
reported to reduce the risk of subsequent childhood leukaemia in
four of the five previously-cited studies. Our study is one of the
largest and most comprehensive evaluations of the relationship
between infant vaccinations and childhood ALL. It is also distin-
guished by reliance on written vaccination records, rather than
maternal recall. In addition, our study is one of the first to investi-
gate the relationship between Hib vaccines and childhood ALL.
Administration of the conjugate Hib vaccine was associated with a
reduced risk of subsequent childhood ALL. The polysaccharide
Hib vaccine exhibited no such inverse association. In the conju-
gate vaccine, the Hib capsular polysaccharide is covalently bound
(i.e. ￿conjugated￿) to a highly immunogenic protein antigen,
yielding an antibody response which begins earlier (at a younger
age), rises higher, and lasts longer than that which follows vacci-
nation with the unconjugated polysaccharide (Wenger et al, 1989).
Although the mechanism of any anti-leukaemic effect of vaccina-
tion remains to be elucidated, it is at least plausible that such an
effect would be more pronounced with the conjugate vaccine.
In contrast with four previous studies (Kneale et al, 1986;
McKinney et al, 1987; Nishi and Miyake, 1989; Kaatsch et al,
1996), our data provide no evidence of a reduced ALL risk
following vaccination with DTP, MMR, or OPV. Our failure to
detect such inverse associations may be due to a lack of statistical
power, because DTP, MMR and OPV were nearly universal among
both cases and controls. There are other possible reasons for this
discrepancy, however. Our study differed in several methodologic
aspects from previous investigations. Only one previous study
(Innis, 1965) obtained vaccine data from written records, only one
(Kneale et al, 1986) included more cases, and only two (Nishi and
Miyake, 1989; Kaatsch et al, 1996) focused specifically on ALL.
While four of the previous studies (Kneale et al, 1986; McKinney
et al, 1987; Nishi and Miyake, 1989; Kaatsch et al, 1996) utilized
age-matched controls, only one (Kaatsch et al, 1996) adjusted for
socioeconomic status. Only one previous study (Nishi and Miyake,
1989) separately reported the relative risks and 95% confidence
intervals for childhood leukaemia following specific vaccinations;
other studies reported the effect of specific vaccines on all malig-
nancies combined (Kneale et al, 1986), and/or the effect of
vaccines in general on childhood leukaemia in particular (Innis,
1965; Kneale et al, 1986; McKinney et al, 1987; Kaatsch et al,
1996).
The apparent reduced risk of ALL after receiving conjugate Hib
vaccine may have been a chance finding, perhaps due to multiple
comparisons. Another possible explanation of the results for Hib
vaccine may be bias, since controls selected using random-digit
dialing were more likely to be offspring of parents with higher
education and/or family income compared with cases (Kleinerman
et al, 1997). While this may explain the tendency of the controls to
have more vaccinations, the association between conjugate Hib
vaccine and ALL persisted after statistical adjustment for family
income and parental education, and no such inverse association
was observed for any other vaccine. Confounding by socio-
economic status may be more plausible for the Hib vaccine than
for other vaccines, since parents of higher socioeconomic status
may have been more inclined to avail themselves of the newly-
introduced, voluntary Hib vaccine.
Because both age and calendar time are strongly related to Hib
vaccination rate, we controlled for both temporal factors. Although
we assumed that only the conjugate Hib vaccine was administered
after 31 December 1987, the polysaccharide vaccine might have
been used sporadically. However, such misclassification would have
reduced the observed inverse association. Other important limita-
tions of our study were the use of random-digit dialing to identify
controls, and the attendant low response rate (only 50%) for
controls. The response rate was lower than that for other compo-
nents of the study because written vaccination records with dates of
vaccination were required; nonetheless, because of the requirement
for written records, this is one of the largest and most stringent
investigations to date of the role of vaccinations in childhood ALL.
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Table 2 Effect of vaccination (ever vs never) on subsequent risk of childhood acute lymphoblastic leukaemia (439 matched pairs)
Vaccine Cases Controls RRa 95% CIb
Measles–mumps–rubella 395 (90%) 394 (90%) 1.19 (0.67–2.10)
Oral poliovirus 429 (98%) 428 (97%) 1.05 (0.41–2.67)
Diphtheria–tetanus–pertussis 424 (97%) 428 (97%) 0.66 (0.27–1.65)
Tetanus (all) 431 (98%) 430 (98%) 0.75 (0.26–2.16)
Diphtheria (all) 431 (98%) 430 (98%) 0.75 (0.26–2.16)
Haemophilus influenzae b (Hib) 206 (47%) 232 (53%) 0.73 (0.50–1.06)
(Presumptive) polysaccharide vaccine 53 (12%) 50 (11%) 1.13 (0.64–1.98)
(Presumptive) conjugate vaccine 153 (35%) 182 (41%) 0.57 (0.36–0.89)
aRelative risk, adjusted for age at censoring, year of birth, sex, race, family income, parental education and attendance at day-care and/or preschool. 
bNinety-five per cent confidence interval.We believe that our findings justify a more definitive investiga-
tion of this question because of the important scientific and public
health implications if our findings for the Hib vaccine are
confirmed. Future studies should utilize population-based cases
and controls matched as closely as possible on date of birth, with
vaccination histories obtained from medical records. Cohort
studies comparing the incidence of leukaemia among subjects who
participated in randomized clinical trials of the conjugate Hib
vaccine, or other vaccines, would offer stronger evidence to
support or refute a reduced ALL risk following vaccination.
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